Granocyte

Granocyte is a pharmaceutical product that contains the active ingredient lenograstim, a granulocyte colony‑stimulating factor (G‑CSF) analog, supplied as an injectable solution for intravenous or subcutaneous administration. It is marketed in the European Union and is available by prescription only. Lenograstim works by binding to G‑CSF receptors on hematopoietic cells, promoting the proliferation and maturation of neutrophil precursors. Thereby, it supports the body's ability to fight infections.

Granocyte is indicated for the management of neutropenia in several clinical settings where rapid restoration of neutrophil counts is needed. The drug is used to accelerate neutrophil recovery, thereby decreasing infection risk during periods of bone‑marrow suppression. - Chemotherapy‑induced neutropenia in adult patients. - Neutropenia following allogeneic or autologous bone‑marrow transplantation. - Severe chronic neutropenia of congenital or acquired origin. - Supportive care to reduce the duration of severe neutropenia during high‑dose myeloablative regimens. - Off‑label use in certain investigational protocols (subject to clinical trial approval). - Prevention of febrile neutropenia in patients receiving dose‑dense chemotherapy schedules.

Granocyte can cause adverse reactions ranging from mild, self‑limiting symptoms to rare but potentially life‑threatening events. Most patients experience only minor effects, while clinicians monitor for serious complications during therapy. Common: - Bone pain, often localized to the back, hips or sternum, typically appearing within hours after injection and usually manageable with analgesics. - Mild fever, chills, or localized erythema at the injection site, which generally resolves without intervention. - Transient fatigue, mild nausea, or headache that are short‑lived and do not require specific treatment. Serious: - Anaphylactic or severe hypersensitivity reactions, including rash, swelling, bronchospasm, or hypotension, requiring immediate medical attention. - Splenic rupture or significant splenomegaly, presenting as acute abdominal pain and requiring imaging and possible surgical intervention. - Marked leukocytosis or thromboembolic complications such as deep‑vein thrombosis, which may necessitate anticoagulation and close hematologic monitoring.

When prescribing Granocyte, clinicians should consider several precautionary measures to ensure patient safety and optimal therapeutic outcome. - Assess baseline neutrophil count and overall bone‑marrow function before initiating therapy. - Use caution in patients with a history of hypersensitivity to recombinant G‑CSF products. - Monitor for signs of splenic enlargement or abdominal discomfort during treatment. - Evaluate for active infections, as rapid neutrophil recovery may mask clinical presentation. - Adjust dosing or discontinue if severe leukocytosis or thromboembolic events develop. - Consider pregnancy and lactation status; limited data are available, so use only if potential benefit outweighs risk.

Granocyte may interact with other agents that influence hematologic parameters or immune responses; awareness of these interactions helps avoid adverse outcomes. Avoid: - Concurrent use of other granulocyte colony‑stimulating factors, which can increase the risk of excessive leukocytosis. - Live vaccines administered during therapy, as enhanced immune response may alter vaccine efficacy or safety. Use with caution: - Chemotherapeutic agents that cause profound bone‑marrow suppression, requiring close monitoring of blood counts. - Anticoagulants or antiplatelet drugs, because rapid neutrophil recovery may affect coagulation balance. - Corticosteroids, which can modulate the pharmacodynamic response to G‑CSF.